GLA
SAGE

Great Lakes Advisors’s Sage Therapeutics SAGE Stock Holding History

Great Lakes Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-207,692
Closed -$18M – 731
2020
Q4 		$18M Buy
+207,692
New +$15.3M 0.33% 100
2017
Q4 		– Sell
-3,853
Closed -$240K – 606
2017
Q3 		$240K Buy
+3,853
New +$303K 0.01% 553

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Great Lakes Advisors's SAGE Position: Q1 2021 in Review

Great Lakes Advisors sold out of Sage Therapeutics (SAGE) in Q1 2021, closing a stake of 207,692 shares — an estimated $18M sold.

Great Lakes Advisors first reported a position in SAGE in Q3 2017 and held it in 2 quarters. The position peaked at $18M in Q4 2020. 262 funds tracked by Wall St. Rank hold SAGE as of Q1 2021.

  • Great Lakes Advisors reported no remaining Sage Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Great Lakes Advisors sold 207,692 Sage Therapeutics shares in Q1 2021, an estimated $18M.
  • Great Lakes Advisors first reported a position in Sage Therapeutics in Q3 2017 and held it in 2 quarters.
  • Great Lakes Advisors's Sage Therapeutics position peaked at $18M in Q4 2020.
  • 262 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2021.

Based on Great Lakes Advisors's 13F filing for Q1 2021, filed 3 May 2021.